TREATMENT SEQUENCING PATTERNS AND COSTS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：4
|
作者：
Potluri, R. [1 ]
Farr, A. M. [2 ]
Hirji, I [3 ]
Davis, C. [4 ]
Bhandari, H. [5 ]
Oukessou, A. [4 ]
机构：
[1] SmartAnalyst Inc, New York, NY USA
[2] Truven Hlth Analyt, Bethesda, MD USA
[3] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[4] Bristol Myers Squibb Co, Princeton, NJ USA
[5] SmartAnalyst India Pvt Ltd, Gurgaon, India
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1134
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN118
引用
收藏
页码：A450 / A450
页数：1
相关论文
共 50 条
  • [31] Patterns of CNS Involvement in Relapsed and/or Refractory Multiple Myeloma
    Abdallah, Al-Ola
    Atrash, Shebli
    Muzaffar, Jameel
    Ahmad, Nisar
    Haider, Sajjad
    Grazziutti, Monica
    Apewokin, Senu
    Shahid, Zainab
    Restrepo, Alejandro
    Waheed, Sarah
    van Rhee, Frits
    Barlogie, Bart
    Usmani, Saad Z.
    BLOOD, 2012, 120 (21)
  • [32] Treatment Options for Relapsed and Refractory Multiple Myeloma
    Lonial, Sagar
    Mitsiades, Constantine S.
    Richardson, Paul G.
    CLINICAL CANCER RESEARCH, 2011, 17 (06) : 1264 - 1277
  • [33] Lenalidomide for the treatment of relapsed or refractory multiple myeloma
    Weber, D. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 22 - 24
  • [34] Elotuzumab in the treatment of relapsed and refractory multiple myeloma
    Grosicki, Sebastian
    Bednarczyk, Martyna
    Barchnicka, Agnieszka
    Grosicka, Olga
    FUTURE ONCOLOGY, 2021, 17 (13) : 1581 - 1591
  • [35] Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
    Bumma, Naresh
    Richter, Joshua
    Jagannath, Sundar
    Lee, Hans C.
    Hoffman, James E.
    Suvannasankha, Attaya
    Zonder, Jeffrey A.
    Shah, Mansi R.
    Lentzsch, Suzanne
    Baz, Rachid
    Maly, Joseph J.
    Namburi, Swathi
    Pianko, Matthew J.
    Ye, Jing Christine
    Wu, Ka Lung
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Byun, Ja Min
    Martinez-Lopez, Joaquin
    Cassady, Kaniel
    Deveaux, Michelle
    Chokshi, Dhruti
    Boyapati, Anita
    Hazra, Anasuya
    Yancopoulos, George D.
    Sirulnik, L. Andres
    Lorenc, Karen Rodriguez
    Kroog, Glenn S.
    Houvras, Yariv
    Dhodapkar, Madhav V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (22)
  • [36] Pomalidomide for the treatment of relapsed and refractory multiple myeloma
    Guidetti, Anna
    Prada, Claudia Paba
    Laubach, Jacob P.
    Varga, Cindy
    Maglio, Michelle E.
    McKenney, Mary
    Doss, Deborah
    Schlossman, Robert L.
    Mitsiades, Constantine
    Hideshima, Teru
    Gorgun, Gullu T.
    Ghobrial, Irene M.
    Raje, Noopur
    Munshi, Nikhil
    Anderson, Kenneth C.
    Richardson, Paul G.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (10): : 1089 - 1108
  • [37] Thalidomide for the treatment of relapsed and refractory multiple myeloma
    Cool, RM
    Herrington, JD
    PHARMACOTHERAPY, 2002, 22 (08): : 1019 - 1028
  • [38] Isatuximab for the treatment of relapsed/refractory multiple myeloma
    Richardson, Paul G.
    Beksac, Meral
    Spicka, Ivan
    Mikhael, Joseph
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (12) : 1395 - 1403
  • [39] Treatment options for relapsed and refractory multiple myeloma
    Nooka, Ajay K.
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    Lonial, Sagar
    BLOOD, 2015, 125 (20) : 3085 - 3099
  • [40] TREATMENT PATTERNS OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN EUROPE (EU-28)
    Gatopoulou, X.
    Bardenheuer, K.
    Van Hoorenbeeck, S.
    Kempel, A.
    VALUE IN HEALTH, 2016, 19 (07) : A715 - A716
12345